The UK’s Veterinary Medicines Directorate (VMD) has completed an extensive safety review of Librela, a widely used injection for managing osteoarthritis pain in dogs, confirming that the medicine’s benefits continue to outweigh its risks for the vast majority of treated animals.
For many African, Caribbean and wider diaspora families across the UK, dogs are not just pets, they are companions, protectors and cherished members of the household. News of concerns surrounding Librela had sparked anxiety among some owners, particularly those whose older dogs rely on the treatment to maintain mobility and quality of life. The VMD’s latest findings aim to provide reassurance while encouraging responsible monitoring and reporting.
Librela, first authorised for use in the UK in November 2020, is designed to relieve pain associated with osteoarthritis in dogs. Osteoarthritis is common in older pets and can severely affect movement, mood and overall wellbeing. Many dogs treated with Librela experience significant improvement in comfort and mobility.
However, as with all medicines, there is a possibility of adverse events. The VMD acknowledged concerns raised by some dog owners and veterinary professionals and undertook an in-depth analysis covering reports of death, rapid progression of arthritis, lack of efficacy, muscle weakness, tremor, recumbency, lameness and human exposure incidents.
Gavin Hall, Director of Authorisations and Deputy Chief Executive Officer at the VMD, said the regulator takes every safety report seriously. He confirmed that, based on all available evidence and independent analysis, Librela’s overall benefit-risk balance remains positive for most dogs. He noted that monoclonal antibody products, like many advanced treatments, are not entirely risk-free.
Recent updates to the product’s official information reflect ongoing monitoring. In January 2026, event terms including immune-mediated polyarthritis, paresis and paralysis were added to the product information to ensure transparency and reflect the latest available data. The VMD continues to review new evidence as it emerges and has committed to updating guidance whenever necessary.
According to UK data, adverse events following Librela administration are classified as uncommon, occurring in approximately one to ten animals per 1,000 treated. Reports of death are considered rare, affecting between one and ten animals per 10,000 treated. The regulator emphasised that Librela is primarily used in older dogs, many of whom have existing health conditions or are taking multiple medications. This can make it more complex to determine whether a specific adverse event is directly linked to the injection.
Veterinary professionals are being advised to carefully review the Summary of Product Characteristics before prescribing Librela, monitor patients closely during treatment and promptly report suspected adverse events to Zoetis, the company responsible for the product. The VMD will also write directly to veterinary professionals detailing the outcome of its review and outlining the latest updates.
Dog owners are encouraged to speak openly with their vets about any concerns and to read the Product Information Leaflet thoroughly before treatment. If a dog appears unwell after receiving Librela, owners should contact their veterinary practice immediately.
Within diaspora communities, where pets often play an emotional support role and veterinary costs can be significant, clarity and trust in regulation are vital. The VMD’s statement reinforces that its role is to protect animal health and welfare through continuous pharmacovigilance. The regulator monitors safety data for all authorised veterinary medicines and will take action if future evidence suggests the risks outweigh the benefits.
Owners and vets can access the latest product information and safety updates through the VMD’s Product Information Database and the gov.uk page dedicated to urgent veterinary medicine safety updates.
As conversations around animal welfare continue to grow within Britain’s diverse communities, Chijos News will keep readers informed with trusted, accessible reporting that matters to diaspora families and pet owners alike.
